<!DOCTYPE html>
<html>
    <head>
        <title>300x250</title>

        <meta name="ad.size" content="width=300,height=250" />
        <meta name="viewport" content="width=device-width, initial-scale=1" />
        <meta charset="UTF-8" />

        <link rel="stylesheet" href="assets/libs/main.css" />
    </head>

    <body>
        <button style="position:fixed;top:10px;left:10px;padding:8px 12px;background:rgba(0,0,0,0.9);color:white;border:1px solid rgba(255,255,255,0.6);cursor:pointer;font-size:12px;z-index:99999;border-radius:3px;font-family:Arial,sans-serif" onclick="history.back()">✕ Cerrar</button>
        <script type="text/javascript" src="assets/libs/gsap3.8.0.js"></script>

        <div class="border"></div>

        <a onclick="gotoLink()" id="clickTag"></a>

        <div id="meckAdd">
            <div class="animation">
                <div class="frame frame1" style="pointer-events: none;">

                    <img class="frame0" src="assets/images/img_1.png" />
                    <img class="bg_blue" src="assets/images/bg_blue.jpg" />
                    <img class="welireg" src="assets/images/welireg.png" />
                    <img class="textind" src="assets/images/ind.png" />
                    <!-- <div>
                        <p class="copy1">
                            <strong>WELIREG</strong> is indicated for the treatment of adult patients <br>
                            with advanced renal cell carcinoma (RCC) following a <br>
                            programmed death receptor-1 (PD-1) or programmed <br>
                            death-ligand 1 (PD-L1) <span style="letter-spacing: -0.1px;">inhibitor and a vascular endothelial</span> <br>
                            growth factor tyrosine kinase inhibitor (VEGF-TKI).
                        </p>
                    </div> -->

                    <img class="man" src="assets/images/man.jpg" />

                    <img class="text1" src="assets/images/txt-1.png" />
                    <img class="text2" src="assets/images/txt-2.png" />

                    <img class="end" src="assets/images/end.jpg" />
                    <img class="merck" src="assets/images/logo-merck.png" />
                    <img class="welireg_last" src="assets/images/welireg.png" />

                    <img class="cta" src="assets/images/cta.svg" />
                    
                    
                </div>
            </div>
            <div id="ssi">
                <div class="title">
                    <h3>Selected Safety Information</h3>
                </div>

                <div class="content">
                    <div class="swiper-container">
                        <div class="top-title" style="display: none;">
                            <div class="title-box">
                                <div class="title1-2">
                                    <h2></h2>
                                </div>
                                <div class="title2-2">
                                    <h2></h2>
                                </div>
                            </div>
                        </div>
                        <div class="swiper-wrapper">
                            <div class="swiper-slide">
                                <div class="slide-inner">
                                    <div class="">
                                        <div class="info_ssi key_info">
                                            <p style="margin-bottom: 4px;">
                                                <strong>WARNING: EMBRYO-FETAL TOXICITY</strong>
                                            </p>
                                            <ul style="margin-bottom: 10px;">
                                                <li>
                                                    <strong>Exposure to WELIREG during pregnancy can cause embryo-fetal harm. </strong>
                                                </li>

                                                <li><strong>Verify pregnancy status prior to the initiation of WELIREG.</strong> <br /></li>
                                                <li>
                                                    <strong>Advise patients of these risks and the need for effective non-hormonal contraception as WELIREG can render some hormonal contraceptives ineffective.</strong>
                                                </li>
                                            </ul>
                                            <p class="blue">
                                                <strong>Anemia</strong>
                                            </p>
                                            <ul style="margin-bottom: 10px;">
                                                <li>
                                                    WELIREG can cause severe anemia that can require blood transfusion.
                                                </li>
                                                <table width="100%" border="0" cellspacing="0" cellpadding="0" style="padding-bottom: 4px;">
                                                    <tbody style="font-size: 11px; line-height: 13px; color: #000000;">
                                                        <tr>
                                                            <td width="5%" valign="top" style="color: #d73327;"><b>–</b></td>
                                                            <td width="95%">
                                                                Monitor for anemia before initiation of, and periodically throughout, treatment. Transfuse patients as clinically indicated. For patients with hemoglobin
                                                                <span style="white-space: nowrap;"> &lt;8 g/dL,</span> withhold WELIREG until <span style="white-space: nowrap;">≥8 g/dL,</span> then resume at the same or reduced dose or
                                                                permanently discontinue WELIREG, depending on the severity of anemia. For life-threatening anemia or when urgent intervention is indicated, withhold WELIREG until <br />
                                                                hemoglobin ≥8 g/dL, then resume at a reduced dose or permanently discontinue WELIREG.
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>

                                                <li>
                                                    In LITESPARK-004 (N=61), decreased hemoglobin occurred in 93% of patients with VHL disease and 7% had Grade 3 events. Median time to onset of anemia was 31 days (range: 1 day to 8.4 months).
                                                </li>

                                                <li>
                                                    The safety of erythropoiesis-stimulating agents (ESAs) for treatment of anemia in patients with VHL disease treated with WELIREG has not been established.
                                                </li>
                                            </ul>
                                            <p class="blue">
                                                <strong>Hypoxia</strong>
                                            </p>
                                            <ul style="margin-bottom: 10px;">
                                                <li>
                                                    WELIREG can cause severe hypoxia that may require discontinuation, supplemental oxygen, or hospitalization.
                                                </li>
                                                <li>
                                                    Monitor oxygen saturation before initiation of, and periodically throughout, treatment. For decreased oxygen saturation with exercise (eg, pulse <br />
                                                    oximeter &lt;88% or PaO<span style="font-family: Arial, Helvetica, sans-serif; font-size: 6px; line-height: 0; vertical-align: -2px;">2</span> ≤55 mm Hg), consider withholding WELIREG until pulse oximetry with 
                                                    exercise is greater than 88%, then resume at the same or a reduced dose. For decreased oxygen
                                                    saturation at rest (eg, pulse oximeter &lt;88% or <br>
                                                    PaO<span style="font-family: Arial, Helvetica, sans-serif; font-size: 6px; line-height: 0; vertical-align: -2px;">2</span> ≤55 mm Hg) or when urgent intervention is indicated, withhold WELIREG until 
                                                    resolved and resume at a reduced dose or discontinue. For
                                                    life-threatening or recurrent symptomatic hypoxia, permanently discontinue WELIREG. Advise patients to report signs and symptoms of hypoxia immediately to a health care provider.
                                                </li>
                                                <li>
                                                    In LITESPARK-004, hypoxia occurred in 1.6% of patients.
                                                </li>
                                            </ul>
                                            <p class="blue">
                                                <strong>Embryo-Fetal Toxicity</strong>
                                            </p>
                                            <ul style="margin-bottom: 15px;">
                                                <li>
                                                    Based on findings in animals, WELIREG can <br />
                                                    cause fetal harm when administered to a pregnant woman.
                                                </li>
                                                <li>
                                                    Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective non-hormonal contraception during
                                                    treatment with WELIREG and for 1 week after the last dose. WELIREG can render some hormonal contraceptives ineffective. Advise male patients <br />
                                                    with female partners of reproductive potential to <br />
                                                    use effective contraception during treatment with WELIREG and for 1 week after the last dose.
                                                </li>
                                            </ul>
                                            <p class="blue">
                                                <strong>Adverse Reactions</strong>
                                            </p>
                                            <ul style="margin-bottom: 15px;">
                                                <li>
                                                    In LITESPARK-004, serious adverse reactions occurred in 15% of patients, including anemia, hypoxia, anaphylaxis reaction, retinal detachment, and central retinal vein occlusion (1 patient each).
                                                </li>
                                                <li>
                                                    WELIREG was permanently discontinued due to adverse reactions in 3.3% of patients for dizziness and opioid overdose (1.6% each).
                                                </li>
                                                <li>
                                                    Dosage interruptions due to an adverse reaction occurred in 39% of patients. Those which required dosage interruption in >2% of patients were fatigue, decreased hemoglobin, anemia, nausea, abdominal pain, headache, and influenza-like illness.
                                                </li>
                                                <li>
                                                    Dose reductions due to an adverse reaction occurred in 13% of patients. The most frequently reported adverse reaction which required dose reduction was fatigue (7%).
                                                </li>
                                                <li>
                                                    The most common adverse reactions (≥25%), including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin (93%), fatigue (64%), increased creatinine (64%), headache (39%), dizziness (38%), increased glucose (34%), and nausea (31%).
                                                </li>
                                            </ul>
                                            <p class="blue">
                                                <strong>Drug Interactions</strong>
                                            </p>
                                            <ul style="margin-bottom: 15px;">
                                                <li>
                                                    Coadministration of WELIREG with inhibitors of UGT2B17 or CYP2C19 increases plasma <br />
                                                    exposure of belzutifan, which may increase the incidence and severity of adverse reactions. Monitor for anemia and hypoxia and reduce the dosage of WELIREG as recommended.
                                                </li>
                                                <li>
                                                    Coadministration of WELIREG with CYP3A4 substrates decreases concentrations of CYP3A4 substrates, which may reduce the efficacy of <br />
                                                    these substrates or lead to therapeutic failures. Avoid coadministration with sensitive CYP3A4 substrates. If coadministration cannot be avoided, increase the sensitive CYP3A4 substrate
                                                    dosage <br />
                                                    in accordance with its Prescribing Information. Coadministration of WELIREG with hormonal contraceptives may lead to contraceptive failure or an increase in breakthrough bleeding.
                                                </li>
                                            </ul>
                                            <p class="blue">
                                                <strong>Lactation</strong>
                                            </p>
                                            <ul style="margin-bottom: 15px;">
                                                <li>
                                                    Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with WELIREG and for 1 week after the last dose.
                                                </li>
                                            </ul>
                                            <p class="blue">
                                                <strong>Females and Males of Reproductive Potential</strong>
                                            </p>
                                            <ul style="margin-bottom: 15px;">
                                                <li>
                                                    WELIREG can cause fetal harm when <br />
                                                    administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to initiating treatment with <br />
                                                    WELIREG.
                                                </li>
                                                <li>
                                                    Use of WELIREG may reduce the efficacy of hormonal contraceptives. Advise females of reproductive potential to use effective non-<br />
                                                    hormonal contraception during treatment with WELIREG and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during
                                                    treatment with WELIREG and for 1 week after the last dose.
                                                </li>
                                                <li>
                                                    Based on findings in animals, WELIREG may impair fertility in males and females of <br />
                                                    reproductive potential and the reversibility of this effect is unknown.
                                                </li>
                                            </ul>
                                            <p class="blue">
                                                <strong>Pediatric Use</strong>
                                            </p>
                                            <ul style="margin-bottom: 15px;">
                                                <li>
                                                    Safety and effectiveness of WELIREG in pediatric patients under 18 years of age have not been established.
                                                </li>
                                            </ul>

                                            <p style="margin-bottom: 10px;">
                                                <strong>
                                                    Before prescribing WELIREG, please read the accompanying <a href="https://www.merck.com/product/usa/pi_circulars/w/welireg/welireg_pi.pdf" target="_blank">Prescribing Information</a>,
                                                    <br />
                                                    including the Boxed Warning about embryo-fetal toxicity. The <a href="https://www.merck.com/product/usa/pi_circulars/w/welireg/welireg_mg.pdf" target="_blank">Medication Guide</a> also is
                                                    available.
                                                </strong>
                                            </p>

                                            <p style="color: #333333; margin-bottom: 10px; font-size: 9px; line-height: 11px;">
                                                <strong>References: 1.</strong> Narayan V, Jonasch E. Systemic therapy development in von Hippel–Lindau disease: an outsized contribution from an orphan disease. <i>Cancers (Basel)</i>. 2022;14(21):5313. <strong>2.</strong> Center for Drug Evaluation and Research. <i>Advancing Health Through Innovation: New Drug Therapy Approvals 2021</i>. https://www.fda.gov/media/155227/download. Accessed February 6, 2024.
                                            </p>

                                            <p style="color: #333333;margin-bottom: 10px;">
                                                Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
                                            </p>

                                            <div class="josb">
                                                <img src="assets/images/logo-merck.png" />
                                                <p style="margin-bottom: 0;color: #333333;padding-top: 4px;">US-BEL-01142&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;04/24</p>
                                            </div>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="swiper-scrollbar"></div>
                    <div class="top-button" style="display: none;"></div>
                    <div class="bottom-button" style="display: none;"></div>
                </div>

                <div class="footer">
                    <a href="https://www.merck.com/product/usa/pi_circulars/w/welireg/welireg_mg.pdf" target="_blank">Medication Guide</a>
                    <a href="https://www.merck.com/product/usa/pi_circulars/w/welireg/welireg_pi.pdf" target="_blank">Prescribing Information</a>
                </div>
            </div>
        </div>

        <script type="text/javascript" src="assets/libs/swiper.4.0.2.js"></script>
        <script type="text/javascript" src="main.js"></script>

        <script>
            clickTag = "https://www.welireghcp.com/von-hippel-lindau/efficacy/";

            var bannerTag = document.getElementById("clickTag");
            var btnCTA = document.getElementById("mainBtn");

            function gotoLink() {
                window.open(clickTag, "_blank");
            }
        </script>
    </body>
</html>
